Allergan plc, AGN is in the exchange NYSE and its industry is Drugs – Generic in the sector of Healthcare. Based in USA, Allergan plc, AGN has a market cap of 97199.69. Since its IPO date on the 2/17/1993, Allergan plc, AGN performance year to date is -23.17%. Today Allergan plc, AGN has gained -0.05%, with a current price of 240.1.
Ownership of the company is 0.10% for insider ownership while institutional ownership is 87.60%. The management of the company have seen the company have a payout ratio of 0.00%. Return of assets are at 3.00%, with return on investment at -1.30%.
In terms of debt levels and profit levels, Allergan plc, AGN is seeing a long-term debt/equity of 0.52. While Total debt/equity is 0.56. With a profit margin of 27.00%, this is combined with a gross margin of 78.70%, and operating margin of -16.50%. Allergan plc ability to meet debt levels, with a current ratio of 1, while the quick ratio is 0.9.
For the last year Allergan plc, AGN has seen a EPS growth of 23.00%. A performance for the year of -18.87%. The 52-week high is -25.59%, and the 52-week low is 22.81%. The average volume for Allergan plc, AGN is 2957200.
With a target price of 299.06, can Allergan plc, AGN reach this target? Looking at the value indicators of Allergan plc, AGN. Allergan plc has a P/E of *TBA and a forward P/E of 14.06. Perhaps the more useful indicator than P/E, is PEG which has a value of *TBA. Allergan plc also has a P/S and a P/B of 6.32 and 1.32 respectively. For P/cash, Allergan plc has a value of 191.87, while it is 22.04 for P/free cash flow.
At the current price of 240.1, Allergan plc has a dividend yield of *TBA. We see a return on equity of 5.70%.
Looking more long-term Allergan plc, is projected to get an EPS growth for the next five years of 13.49%. In the short-term an EPS growth of 21.93% in the next year is forecasted. This is after a EPS growth of 23.00% for this year and for the last five years a -50.40% growth has been seen.